Low-dose chemotherapy combined with delayed immunotherapy in the neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of the drug response in peripheral blood

Chaoyang Liang[1†], Qi Song[2†], Wenhao Zhou[3†], Na Li[3†], Qi Xiong[2], Chaohu Pan[3], Shaohong Zhao[4], Xiang Yan[2], Xiaoling Zhang[2], Yaping Long[5], Juntang Guo[1], Tao Wang[1], Weiwei Shi[2], Shengjie Sun[2], Bo Yang[1], Zhouhuan Dong[6], Haitao Luo[3*], Jie Li[6*], Yi Hu[2*], and Bo Yang[2*]

[1]Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.

[2]Department of Oncology, Chinese PLA General Hospital, Beijing, China.

[3]Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, China.

[4]Department of Radiology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.

[5]School of Medicine, Nankai University, Tianjin, China.

[6]Department of Pathology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.

[†]Chaoyang Liang, Qi Song, Wenhao Zhou, and Na Li contributed equally to this work.

** Correspondence

Bo Yang: yangbo@301hospital.com.cn

Yi Hu: huyi@301hosptial.com.cn

Jie Li: lijiek812@301hospital.com.cn

Haitao Luo: luohhaitao@yucebio.com

Abstract

Background: Despite chemo-immunotherapy has been applied to the neoadjuvant treatment of non-small cell lung cancer (NSCLC), the impacts of dosage and the order of medication on treatment efficacy and safety remain largely unexplored. We originally designed an exploratory study to investigate the efficacy and safety of reduced-dose chemotherapy combined with delayed immunotherapy as well as the dynamic changes of circulating tumor DNA (ctDNA) and T cell receptor (TCR) during the therapy.

Methods: Patients with clinical stage IIA to IIIA resectable NSCLC were treated with 2 cycles of reduced-dose platinum-based chemotherapy on day 1 combined with immunotherapy on day 5. The same postoperative modified adjuvant therapy regimen was administered for 2 cycles. Plasma samples at different time-points were collected and performed with T cell receptor (TCR) and circulating tumor DNA (ctDNA) sequencing.

Results: 38 patients received modified chemo-immunotherapy. The proportion of patients exhibiting complete response and partial response was 5.3% and 68.4%, respectively. The confirmed objective response rate was 73.7%. Radiological downstaging was achieved in 39.5%. Major pathologic response and complete pathologic response were observed in 47.4% and 31.6% of patients, respectively. Only one patient experienced grade 3 adverse event. Further analyses revealed that this modified chemo-immunotherapy led to the expansion of predominant TCR clones and reduction of tumor burden after the first cycle of chemotherapy.

Conclusion: The promising clinical efficacy and low side effects of modified neoadjuvant chemo-immunotherapy position it as a prospective and innovative strategy for NSCLC.

Funding: This study was funded by the National Natural Science Fund of the People's Republic of China (NSFC; No.81902912).

Trial registration: Registration Number: ChiCTR2000033092

Keywords: Non-small cell lung cancer, Modified neoadjuvant chemo-immunotherapy, Low-dose chemotherapy, Delayed immunotherapy, Treatment efficacy, Side effects, Circulating tumor DNA, T cell receptor

Background

Approximately 20 to 25% of patients diagnosed with NSCLC are eligible for surgical resection (1), yet 30% to 55% of those who undergo curative surgery will encounter recurrence and ultimately die (2, 3). Despite the improvement in treatment of NSCLC patients, the 5-year survival rates remain relatively low, hovering around 36% (4). Over the past decade, neoadjuvant platinum-based chemotherapy, followed by surgery, has become the standard of care. Nevertheless, only 5 to 6 % improvements have been noted in 5-year recurrence-free survival and overall survival rates compared to surgery alone (5).

Currently, combination of chemotherapy with immunotherapy has demonstrated superior clinical efficacy and prolonged event-free survival for patients with resectable NSCLC. Trials such as CheckMate 816 (6), SAKK 16/14 (7), and NADIM (8), have showcased the enhanced efficacy and manageable safety of combination therapy compared to monotherapy. However, for most previous clinical trials, cytotoxic drugs with standard doses and anti-PD1 antibody were administrated on the same day (9), which may result in unsatisfactory eradication rates and relatively high incidence of severe treatment-related adverse events (TRAEs). To improve the cure rate and reduce TRAEs, the use of low-dose chemotherapy may represent a feasible alternative, given it favorable tolerability profile without compromising efficacy (10, 11). Although various regimens of low-dose chemotherapy have been utilized in cancer therapy (12, 13), the effects of dosage and administration sequence on the efficacy and safety of NSCLC treatment remain controversial. According to our previous research findings, the administration of immunotherapy 3-5 days after

chemotherapy significantly reduces lymphocyte damage (14). Therefore, we

hypothesize that by coordinating the dosage of chemotherapy and the timing of

immunotherapy administration, we can enhance the synergistic effects between the

two interventions. Ultimately, this could improve clinical efficacy while reducing

toxic side effects.

To monitor the therapeutic efficacy during the process of chemo-immunotherapy,

there is an urgent requirement for reliable indicators. The T cell receptor (TCR)

repertoire and the presence of circulating tumor DNA (ctDNA) in blood have been

proven to be efficient predictors of therapeutic responses in cancer treatment (15, 16).

Chemotherapeutic agents have the capability to induce immunogenic death of tumor

cells, reduce tumor burden, and promote the infiltration of CD8 T lymphocyte (17,

18). The recognition of tumor antigens by CD8 T lymphocytes relies primarily on the

presence of a diverse and polymorphic TCR within an individual (19). Hence, it is

imperative to explore the dynamic changes of TCR diversity and tumor burden in

ctDNA throughout the course of therapy.

In this study, we report the results of our pilot clinical trial assessing the efficacy and

safety of modified neoadjuvant chemo-immunotherapy in patients with resectable

NSCLC. These results indicate that the combination of low-dose chemotherapy

followed by delayed immunotherapy could potentially induce tumor cell damage,

promote antigen exposure, and support T cell expansion, thereby enhancing

therapeutic efficacy and reducing toxic side effects. Monitoring the dynamic changes

of TCR repertoire and ctDNA does not only offer insights into the mechanism

underlying our therapeutic approach to some extent but also furnishes valuable data

for monitoring treatment efficacy.

Materials and Methods

Study design and participants

38 Patients with resectable stage IIA to IIIA NSCLC, as per the staging criteria

outlined by the American Joint Committee on Cancer, 8th edition, and possessing

adequate organ function, along with an Eastern Cooperative Oncology Group

performance-status rating of 0 to 1, were included in this study. All patients had not

received any prior cancer treatment, exhibited measurable disease according to the

Response Evaluation Criteria in Solid Tumors (version 1.1) and had confirmed

histological or cytological evidence of the disease. Exclusion criteria included the

presence of identified *EGFR* mutations or *ALK* translocations; a diagnosis of

malignancies beyond NSCLC within 5 years; previous exposure to specific therapies

such as anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or medications targeting T cell

receptor modulation (e.g., CTLA-4, LAG-3, or TIM-3); a history of allogeneic organ

or hematopoietic stem cell transplantation (except corneal transplantation); ongoing

repercussions from prior interventions; pregnancy or breastfeeding; and HIV

positivity. Moreover, the availability of pre- and post-adjuvant treatment tumor tissues

and serial blood samples facilitated comprehensive analyses including whole

transcriptome sequencing, TCR sequencing, and ctDNA sequencing.

Trial design and treatment

This study was a single-center, single-arm, pilot clinical trial (Registration Number:

ChiCTR2000033092). Eligible patients received 2 cycles of neoadjuvant therapy of

low-dose platinum-based chemotherapy: albumin-bound paclitaxel 180-220 mg/m^2

plus cisplatin 60 mg/m^2 for lung squamous cell carcinoma or pemetrexed disodium

500 mg/m^2 plus cisplatin 60 mg/m^2 for lung adenocarcinoma respectively on day 1

plus sintilimab 200 mg on day 5 of each cycle, followed by radiographic evaluation

before undergoing radical surgery. Surgery was conducted within 6 weeks after the

completion of neoadjuvant treatment. Then patients would receive 2 cycles of

adjuvant therapy with the same regimen.

Study outcomes

The primary endpoints include objective response rate (ORR: the proportion of

patients with complete response (CR) or partial response (PR) according to response

evaluation criteria in solid tumors) and major pathologic response (MPR) (less than

10% residual viable tumor cells in the primary tumor and sampled lymph nodes)

according to the pathologist review. Secondary endpoint included pathologic complete

response (pCR) (0% residual viable tumor cells in the primary tumor and sampled

lymph nodes), disease free survival (DFS), treatment-related adverse events (TRAEs),

occurrence of surgical complications, and intraoperative and perioperative

complications.

Plasma collection, cell-free DNA extraction, and sequencing

Blood samples were collected into cell-free DNA blood streck tubes. Isolated plasma

and paired white blood cell (WBC) control were stored at -80□ until extraction.

Cell-free DNA (cfDNA) and WBC-derived DNA were extracted from 4 mL plasma

and WBC using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany)

and Mag-Bind® Blood & Tissue DNA HDQ 96 kit (OMEGA) according to the

manufacturer's instructions, respectively. DNA extracts were sheared to 100 bp

fragments using an S220 focused ultrasonicator (Covaris, Woodbrun, MA, USA). The

adaptors (NadPrep®) were attached to the terminal of fragments and followed by

PCR (Bio-Rad T100, USA) replication. The libraries were constructed using NadPrep

Plasma Cell-Free DNA Dual-Ended Molecular Tag Library Construction Kit (for MGI)

(Nanodigmbio). The target customized probes YuceOne Plus (ctDNA) synthesized by

IDT were used for hybridization enrichment. Target enrichment was performed with

NadPrep Hybrid Capture Reagents (Nanodigmbio). The enriched DNA fragments

were sequenced with the MGISEQ platform. The mean depth of coverage was 3445×

for cfDNA and 1419× for matched peripheral blood samples.

Circulating tumor DNA (ctDNA) analysis

SOAPnuke was implemented to cut the adapter and remove low-quality raw reads

174 (20). Genecore was performed for cluster reads by unique molecule index (UMI) and

175 remove the replicated reads derived from PCR (21). Clean reads were aligned against

176 the human reference genome (hg19) with BWA (v0.7.12) (22) and duplicated reads

177 were removed by samtools (v0.1.19) (23). Subsequently, generated BAM files were

178 used for downstream analysis. We compared the ctDNA samples and matched control

179 blood sequencing data to identify the somatic mutations, including single nucleotide

180 variants (SNVs) and small insertions and deletions (Indels) using mutation caller

181 Vardict (v1.7.0) with default parameters (24). Next, the caller was run with dbSNP

182 (version 147), 1000G (phase3_release_v5), CLINVAR (version 151 ClinVar

183 (nih.gov)), and COSMIC (version 81) data for known polymorphic sites. Substitutions

184 and indels would be filtered out according to the following criteria: 1) low variant

185 allelic fractions (VAF < 0.0005), 2) removed any variants with greater than 1

186 supporting read in the matched germline sample, 3) variants present in the above

187 genome database. In addition, the filtered mutations were annotated by snpEff (v4.3)

188 (25) with NCBIrefseq (https://www.ncbi.nlm.nih.gov/refseq/). The maximum VAF is

189 considered as the tumor burden during the therapy.

191 **Whole transcriptome sequencing**

192 The total RNA of tumor samples was isolated using the RNeasy FFPE Kit (Qiagen,

193 GER) according to the manufacturer's instructions. The concentrations of RNA were

194 quantified using Qubit™ RNA HS Assay Kit (ThermoFisher Scientific, USA). RNA

195 purity and integrity were checked using the Take3 (BioTek, USA) and the RNA

196 Cartridge kit of the Qseq100 Bio-Fragment Analyzer (Bioptic, CHN), respectively.

197 Then, RNA sequencing (RNA-seq) libraries were constructed using the rRNA

198 depletion module (H/M/R) and NadPrep DNA Library Preparation Module for MGI

199 (MGI, CHN). The libraries were sequenced on the MGISEQ-T7 platform with 100 bp

200 paired-end reads.

202 **RNA-Seq raw data quality control, gene expression analysis, and immune cell**

abundance estimation

Raw sequencing data (raw reads) from MGISEQ-T7 was processed to filter out

low-quality reads. Clean reads from each sample were aligned against the hg19

reference by STAR (v2.7.8) (26). The read counts and transcripts per million (TPM)

values were calculated based on aligned RNA sequencing reads to reference

transcripts downloaded from gencode (v27lift37) database, as implemented in rsem

(v1.3.0) (27). Based on the gene expression matrix, R packages xCell (28) and web

tool ImmunCellAI (29) were used to estimate the infiltration abundance of immune

cells for each sample.

T cell receptor sequencing and analysis

For T cell receptor (TCR) sequencing, total RNA was isolated from peripheral blood

mononuclear cells (PBMCs) by RNeasy Plus Mini Kit (Qiagen, USA) according to

the manufacturer's instructions. Qubit™ RNA HS Assay Kit (ThermoFisher Scientific,

USA) was applied to determine the final concentration. Then TCR β-chain of CDR3

was amplified by Multi-IR Library Prep Kit (iGeneTech, CHN). Sequencing

procedures were utilized by the MGISEQ-T7 platform with 100-bp paired-end reads.

Fastq reads were trimmed based on their low-quality 3' ends to base. Trimmed

pair-end reads were integrated according to overlapping alignment with the modified

Needleman-Wunsch algorithm. MiXCR (v2.1.10) (30) was performed to identify the

CDR3 sequences of V-D-J gene segments with reference sequences from the IMGT

(31). VDJtools (v1.2.1) (32) was utilized to assess the immune repertoire sequencing.

A frequency-based correction was performed on samples. The diversity of the TCR

repertoire was calculated with the Shannon-Wiener index formula

$H = - \sum_{i=0}^{n} p_i \ln p_i$ represents the frequency of clonotype i for the sample with n

unique clonotypes. The evenness of the TCR repertoire was calculated with the

formula $\frac{H}{\ln(s)}$, where H was Shannon Weiner index and S was the total number of

species in a sample, across all samples in the dataset. Clonality is defined as a

normalized Shannon index over n unique clones: clonality $= 1 - H/\ln(n)$. The D50

index was also performed to evaluate the diversity according to the top 50% of the

total TCR clones in the samples. According to clonotype abundance, TCR clonotypes

were defined as large clones when their frequency > 0.001. Based on the frequency

ranking, the top 20 most frequent TCR clones and large clones are defined as the

predominant TCR clones.

Statistical analysis

All statistical analyses were implemented by R 4.0 software or SPSS 27.0. Medians

and inter quartile range (IQRs) were provided for distributions of observation duration

and time intervals. Wilcoxon's Rank-Sum test was used to compare across

independent groups. Wilcoxon's Signed-Rank test was used for the pairwise

comparison samples. All reported *P* values are two-sided, and *P* values less than 0.05

were considered statistically significant.

Results

Overview of the patient cohort

From May 2020 to November 2023, 50 patients diagnosed with NSCLC at stage

IIA-IIIA were screened for eligibility, of which 38 received two cycles of modified

neoadjuvant chemo-immunotherapy (**Fig. 1A**). Each cycle featured two phases,

corresponding to chemotherapy and immunotherapy (**Fig. 1B**). Following modified

neoadjuvant chemo-immunotherapy, 31 patients underwent R0 resection (**Figure 1A**

and Table S1). The postoperative tissues were subjected to pathological evaluation.

Samples from a representative patient (P2) who achieved pCR after neoadjuvant

treatment exhibited morphological alterations, characterized by extracellular mucin

pools and fibrosis (**Fig. 1C**). Computed tomography scans demonstrated the

obliteration of lung lesions following neoadjuvant therapy (**Fig. 1D**). 74.2% (27/31)

participants received the modified adjuvant chemo-immunotherapy (from time-point

c3d0 to c4d21) (**Fig. 1A and B; Table S1**). Detailed treatment regimens are provided

in **Table S2**.

Most patients were men (78.7%) and had a smoking history (81.6%). The median age

of patients was 64 years (range: 37-77). All patients had ECOG performance status of

0 or 1. Baseline patient characteristics are summarized in **Table 1** and detailed in

Table S1.

Clinical efficacy and safety

After neoadjuvant therapy, 39.5% (15/38) patients achieved radiological downstaging

(**Fig. 2A; Table 2**). The ratio of patients with CR, PR, and stable disease (SD) was 5.3%

(2/38), 68.4% (26/38), and 26.3% (10/38), respectively, yielding an ORR of 73.7%

(28/38) (**Fig. 2B**). 91.3% (21 of 23) were recurrence-free (**Fig. 2C**). The median

interval between the last dose of sintilimab and surgery was 33 days (interquartile

ranges (IQRs) 5.55 days) (**Table S1**). 58.1% (18/31) patients achieved a MPR,

including 12 patients with a pCR, and 41.9% (13/31) patients achieved a non-MPR

(**Fig. 2D**).

For patients receiving adjuvant therapy, the median interval between the surgery and

the adjuvant therapy was 32.1 days (IQRs 7.2 days) (**Table S1**). Up to January 18,

2024, the median follow-up was 14.37 months (IQRs 24.22 months) (**Table S1**). The

median OS are not reached (**Fig. 2E**). 44.7% (17/38) patients experienced at least one

TRAE (**Table 3**). Grade 3 TRAEs occurred only in one patient. The most common

grade 1 or 2 TRAEs were nausea (15.8%). Previously unreported toxic effects were

not observed, and there were no instances of discontinuation of modified neoadjuvant

chemo-immunotherapy due to toxicity.

Low-dose chemotherapy combined with delayed immunotherapy has a positive

effect on T lymphocytes

To investigate whether dynamic changes in peripheral blood TCR repertoire were

associated with treatment efficiency during modified chemo-immunotherapy, 49

peripheral blood samples were collected from serial time-points and evaluated using

TCR sequencing (**Fig. 3A**). Since the predominant number of TCR clones is an

important indicator of immune response and treatment efficacy (15, 33-35), the

frequency of the top 20 TCR clones was analyzed at each treatment phase. Significant

increase of top 20 TCR clones were observed in phase 1 to 3 (all $P < 0.0001$; **Fig. 3B;**

Fig. S1). An overall increase of top 20 frequency was observed in the first cycle of

neoadjuvant therapy (C1). In contrast, no significant changes were observed during

adjuvant therapy (**Fig. 3C; Table S3**). These results suggested that the peripheral

blood-derived top 20 TCR clones were phased increased not only during low-dose

chemotherapy, but also during immunotherapy within neoadjuvant therapy.

According to clonotype abundance, the TCR clones were divided into 3 clonotypes,

including large (frequency > 0.001), median (0.001-0.0001), and small (< 0.0001)

clones. A markedly increase of large clones was observed during neoadjuvant therapy

(all $P < 0.05$) (**Fig. 3D and E**), consistent with the trend of top 20 TCR clones. No

significant difference was observed in the diversity, evenness, and clonality of TCR

clones across the whole treatment procedure (**Fig. 3F; Fig. S2; Table S4**). The

changes of T lymphocytes in the tumor microenvironment across the neoadjuvant

therapy were analyzed based on transcriptomic data. As shown in **Figure S3**, the

CD4+ and CD8+ T lymphocytes tended to increase during neoadjuvant therapy.

Collectively, the neoadjuvant treatment had a positive effect on T lymphocytes.

Reduced tumor burden in ctDNA was observed during neoadjuvant therapy

To monitor the dynamic changes of tumor burden in ctDNA during therapy, peripheral

blood samples were collected at serial time-points (T0 to T7) and evaluated via

ctDNA sequencing. The landscape of genomic alternations was shown in Figure 4A.

Among the detected genes, *TP53* (50%) was the most frequently mutated gene,

followed by *ARID1A* (11%), *DNMT3A* (11%), and *PIK3CA* (11%) (**Fig. 4A; Table**

S5). Throughout the entire treatment, the maximal somatic variant allelic frequency (maxVAF) of ctDNA had a declining trend, especially in PH1 (T0 to T1) with dramatically decreased ($P < 0.05$) (**Fig. 4B; Fig. S4**), indicating that low-dose chemotherapy would induce tumor cell death thus reducing tumor burden. Notably, we observed that the changes in TCR and ctDNA exhibited opposite trends during the neoadjuvant therapy (**Fig.3B and 3D; Fig. 4B**). Taken together, these results suggest that low-dose chemotherapy combined with delayed immunotherapy not only cause the increase of tumor antigens shed into blood but also stimulate the body's immunity to produce more tumor antigen-specific T lymphocytes.

Discussion

In recent clinical trials, the combination of neoadjuvant chemotherapy with immunotherapy by administering them concurrently in patients with resectable NSCLC has brought about longer event-free survival (6, 8, 36). Although chemotherapy promotes tumor cell death and T lymphocyte infiltration (17, 18), it may also have negative effects on T lymphocyte proliferation (37). Therefore, in the context of combination therapy, the dosage of chemotherapy and the timing of its administration relative to the other treatment need to be better adjusted to optimize the current therapeutic efficacy.

Our previous findings from both in vitro experiments and clinical trials have suggested that administering PD-1/PD-L1 inhibitors at 1-10 days (especially 3-5 days) after chemotherapy in lung cancer patients may be more effective than administering them before or concurrently (14). In this trial, we reported the safety and efficacy of low-dose platinum-based chemotherapy combined with delayed immunotherapy for patients with stage IIA to IIIA resectable NSCLC. After modified neoadjuvant therapy, ORR was achieved in 73.7% (28/38) of patients, which was higher than the report of CheckMate-816 (54%) (6) and comparable to those of NADIM (76%) (8) and LungMate 002 (76%) (38) trials. MPR was achieved in 47.4% (18/38) patients, with

31.6% (12/38) achieving pCR. During a median follow-up of 14.37 months, 91.3% (21/23) patients were recurrence-free. These results indicated that modified neoadjuvant chemo-immunotherapy was effective in patients with resectable NSCLC. Only 2.6% (1/38) patients experienced serious TRAEs after receiving modified neoadjuvant treatment, which is lower than the rates reported in CheckMate 816 (33.5%), NAMID (30.0%) (8), and LungMate 002 (6.0%) (38) trials. The reduction of chemotherapeutics may contribute to the low incidence of serious TRAEs. Additionally, we did not observe treatment discontinuation due to toxicity. These results provide evidences that low-dose platinum-based chemotherapy combined with delayed immunotherapy as a neoadjuvant therapy is safe and less toxic.

Previous research has illustrated an association between clinical benefit and TCR repertoire as well as ctDNA level at baseline (39, 40). However, the dynamic changes in the TCR repertoire and ctDNA level during neoadjuvant treatment have been less studied. In our study, we found that the predominant TCR clones were greatly increased after the treatment of chemotherapy from phase 1 to 3, indicating that low-dose platinum-based chemotherapy did not inhibit the proliferation of predominant T cell clones which create a beneficial microenvironment for subsequent immunotherapy. Moreover, ICI treatment significantly increased the number of predominant TCR clones during neoadjuvant therapy, suggesting that immunotherapy has a positive impact on TCR clones, consistent with the study by Forde et al (41). During adjuvant therapy, no significant fluctuation in the predominant TCR clones was observed, probably because the tumor lesions were cleared. Under such circumstances, no tumor antigen was released, thus no tumor antigen-specific T cells were proliferated. Similarly, no significant change was observed in evenness or clonality of TCR. MaxVAF of ctDNA was dramatically dropped during phase 1, which is accordance with previous studies (42-44). Notably, the maxVAF of ctDNA and predominant TCR clones showed opposite trends of change in phase 1. Moreover, the maxVAF of ctDNA was close to 0 during adjuvant therapy stage.

Our study had several limitations that need to be acknowledged. First, it was a pilot study with a relatively small cohort and lacked a control arm. Therefore, validation of our findings in larger cohorts is necessary. Second, the follow-up period was short, and longer-term results are needed to investigate whether modified therapy provides long-term survival benefits. Finally, innovative techniques should be incorporated to further explore the underlying mechanisms of superior clinical efficacy and reduced TRAEs.

In this study, the modified neoadjuvant low-dose platinum-based chemotherapy combined with delayed immunotherapy in patients with resectable NSCLC exhibited promising efficacy and feasibility. The multi-omics analyses provide the dynamic trajectories of the TCR repertoire and tumor burden, which can aim in better understanding the mechanisms of superior efficiency and the feasibility of modified chemo-immunotherapy. In the future, it is possible to conduct large-scale clinical research using this modified chemo-immunotherapy.

Acknowledgements

We would like to thank Innovent Biologics, Inc for providing sintilimab for this study.

Author's contributions

C.Y. Liang: Conceptualization, Formal analysis, Methodology, Writing - original draft. Q. Song: Formal analysis, Methodology, Funding acquisition, Writing - original draft. W.H. Zhou and N. Li: Formal analysis, Methodology, Writing - original draft. C.H. Pan, Q. Xiong B. Yang, and X.L Zhang: Formal analysis. S.H Zhao, W.W. Shi, X. Yan, J.T. Guo, S.J. Sun, Z.H. Dong, and Y.P. Long: Validation, Writing - reviewing & editing. B. Yang, J. Li, Y. Hu, and H.T. Luo: Conceptualization, Investigation, Validation, Verification of underlying data, Supervision, Writing - reviewing & editing.

Funding

This study was supported by the National Natural Science Fund of the People's

Republic of China (NSFC) No.81902912.

Data availability statement

All the analysis data can be found in the supplementary tables. The dataset supporting

the conclusions of this article is available in the Genome Sequence Archive for

Human (GSA-H) repository with accession number (HRA002904) and can be

accessed thru the URL (BIG Search - National Genomics Data Center - BIG Search

(cncb.ac.cn)) after reasonable request.

Declarations

Ethics approval and consent to participate

This study was conducted according to the guidelines of the Ethics Committee of the

General Hospital of the People's Liberation Army (S2020-144-01) and written

informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflicts of interest.

References

1. Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage

non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2(5):403-10.

2. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl

Lung Cancer Res. 2014;3(4):242-9.

3.   Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL,

et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann

Thorac Surg. 2012;93(6):1813-20; discussion 20-1.

4.   Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE,

et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM

Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for

Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.

5.   Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a

systematic   review   and   meta-analysis   of   individual   participant   data.

Lancet.383(9928):1561-71.

6.   Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J

Med. 2022.

7.   Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et

al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients

With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase

II Trial. J Clin Oncol. 2021;39(26):2872-80.

8.   Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M,

et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung

cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. The Lancet

Oncology. 2020;21(11):1413-22.

9.   Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New

England journal of medicine.386(21):1973-85.

10. Gangopadhyay A, Nath P, Biswas J. Reduced Dose Intensity of Chemotherapy

may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall

Bladder: An Experience from a Regional Cancer Centre in Eastern India. J

Gastrointest Cancer. 2015;46(3):297-300.

11. Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, et al. Docetaxel maintenance

therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med. 2021;9(4):338.

12. Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-trans plant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical p eripheral blood stem cell transplantation: A multicentre, randomized c ontrolled clinical trial. Br J Haematol.200(2):210-21.

13. Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LO, et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2019;4(5):376-88.

14. Yao W, Zhao X, Gong Y, Zhang M, Zhang L, Wu Q, et al. Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer. ESMO Open. 2021;6(2):100094.

15. Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, et al. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Front Immunol. 2020;11:587014.

16. Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MPS, et al. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020;26(12):2849-58.

17. Gaudreau P-O, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, et al. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident M emory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of thoracic oncology : official publication of the Internation al Association for the Study of Lung Cancer.16(1):127-39.

18. Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted

CXCL11 promoted CD8$^+$ T cells infiltrat ion through docetaxel-induced-release of

HMGB1 in NSCLC. Journal for immunotherapy of cancer.7(1):42.

19. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for

cancer immunotherapy. Science (New York, NY).367(6477):eaax0182.

20. Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. SOAPnuke: a MapReduce

acceleration-supported software for integrated quality control and preprocessing of

high-throughput sequencing data. (2047-217X (Electronic)).

21. Chen S, Zhou Y, Chen Y, Huang T, Liao W, Xu Y, et al. Gencore: an efficient tool

to generate consensus reads for error suppressing and duplicate removing of NGS data.

BMC Bioinformatics. 2019;20(23):606.

22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler

transform. (1367-4811 (Electronic)).

23. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve

years of SAMtools and BCFtools. LID - 10.1093/gigascience/giab008 [doi] LID -

giab008. (2047-217X (Electronic)).

24. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al.

VarDict: a novel and versatile variant caller for next-generation sequ encing in cancer

research. Nucleic acids research.44(11):e108.

25. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for

annotating and predicting the effects of single nucleoti de polymorphisms, SnpEff:

SNPs in the genome of Drosophila melanogaste r strain w1118; iso-2; iso-3. Fly

(Austin).6(2):80-92.

26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:

ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.

27. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data

with or without a reference genome. BMC Bioinformatics. 2011;12:323.

28. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular

heterogeneity landscape. Genome Biology. 2017;18(1):220.

29. Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, et al. ImmuCellAI: A

Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its

Application in Cancer Immunotherapy. Adv Sci (Weinh).7(7):1902880.

30. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva

EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nature

Methods. 2015;12(5):380-1.

31. Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE.

IPD-IMGT/HLA Database. (1362-4962 (Electronic)).

32. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV,

Putintseva EV, et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.

PLoS Comput Biol. 2015;11(11):e1004503.

33. Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, et al.

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic

Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.

Clin Cancer Res. 2020;26(6):1327-37.

34. Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, et al. Peripheral blood T-cell receptor

repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated

with PD-1 inhibitor. Clin Transl Oncol. 2021;23(8):1646-56.

35. Li Y, Wang J, Wu L, Li X, Zhang X, Zhang G, et al. Diversity of Dominant

Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins

Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor

Treatment in Advanced Cancers. Front Immunol. 2021;12:649343.

36. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny

Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

The New England journal of medicine.381(21):2020-31.

37. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks,

consequences, and new directions for its management. Cancer. 2004;100(2):228-37.

38. Zhu X, Sun L, Song N, He W, Xie B, Hu J, et al. Safety and effectiveness of

neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC

(LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20(1):493.

39. van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter Elst A, et al. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Mol Oncol. 2021;15(11):2910-22.

40. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia Campelo MDR, Lazaro M, et al. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clin Cancer Res. 2021;27(21):5878-90.

41. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-86.

42. Jiang T, Jiang L, Dong X, Gu K, Pan Y, Shi Q, et al. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma. Theranostics.11(1):257-67.

43. Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Journal of clinical oncology : official journal of the American Societ y of Clinical Oncology.40(25):2924-33.

44. Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment f or Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of thoracic oncology : official publication of the Internation al Association for the Study of Lung Cancer.17(4):544-57.

Table 1 Baseline clinical characteristics of patients.

Characteristics	Overall (n=38)
Median age (range), years	64 (37-77)
Sex, n (%)	
Male	28 (78.7%)
Female	10 (26.3%)
ECOG performance status, n (%)	
0	8 (21.1%)
1	30 (78.9%)
Histological type, n (%)	
Squamous cell carcinoma	21 (55.3%)
Adenocarcinoma	17 (44.7%)
TNM stage, n (%)	
IIA	3 (7.9%)
IIB	12 (31.6%)
IIIA	23 (60.5%)
Smoking status, n (%)	
Yes	31 (81.6%)
No	7 (18.4%)
PD-L1 TPS, n (%)	
< 1%	17 (44.7%)
1-49%	13 (34.2%)
≥ 50%	8 (21.1%)

579   Data are presented as median (range) or n (%). Abbreviations: ECOG, Eastern Cooperative

580   Oncology Group; TNM, tumor-nodes-metastasis; TPS, tumor proportion score.

582   **Table 2 Response to modified neoadjuvant chemo-immunotherapy**

Response to Treatment	Rate (%), Patient No.
Tumor down-staging rate	39.5% (15/38)
ORR	73.7% (28/38)

R0 resection rate	81.6% (31/38)
pCR rate	38.7% (12/31)
MPR rate	58.1% (18/31)

583 Data are presented as n%. ORR, objective response rate; pCR, pathologic complete response;

584 MPR, major pathological response.

586 **Table 3 Summary of treatment-related adverse events**

Treatment-related adverse events	Grade 1 or 2	Grade 3
n (%)	**16 (42.1%)**	**1 (2.6%)**
Nausea	6 (15.8%)	0
Constipation	3 (7.9%)	0
Decreased appetite	3 (7.9%)	0
Anemia	2 (5.3%)	0
Fever	2 (5.3%)	0
Rash	2 (5.3%)	0
Decreased neutrophil count	2 (5.3%)	0
Diarrhea/colitis	1 (2.6%)	0
Hepatotoxicity	1 (2.6%)	1 (2.6%)
Hypothyroidism	1 (2.6%)	0
Adrenal insufficiency	1 (2.6%)	0
Hyperthyroidism	1 (2.6%)	0
Maculopapular	0	0
Hypersensitivity	0	0
Pneumonitis	0	0
Hypophysitis	0	0
thyroiditis	0	0
Diabetes mellitus	0	0
Neutropenia	0	0

587　　　　　　　　　　　　　　　　　All data are shown as n (%).

Figure Legends

Fig.1 Overview of study design and representative images.

(A) Flow diagram of the study. **(B)** Trial schema of the study. Patients with NSCLC

received modified neoadjuvant chemo-immunotherapy, followed by surgical resection

and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at

baseline and the surgery phase. Serial blood samples were collected at baseline and

each time-point for TCR and ctDNA sequencing. **(C)** Representative hematoxylin and

eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR.

(D) Representative computed tomographic imaging of lung lesions of P2. NSCLC,

non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA;

pCR, pathologic complete response.

Fig.2 Clinical efficacy of modified neoadjuvant chemo-immunotherapy.

(A) Tumor size changes from baseline based on radiological imaging. **(B)** Ring

diagram showed the rate of overall response according to RECIST criteria (CR, PR,

and SD) in patients. **(C)** Swimmer plot of 31 patients who underwent R0 resection

involved in this trial. **(D)** Barplot showed the number of patients distributed in

pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively).

(E) DFS curve for patients with modified treatment. CR, complete response; PR,

partial response; SD, stable disease; pCR, completed pathological response; MPR,

major pathological response; DFS, disease free survival.

Fig. 3 Dynamic changes in T cell repertoire during therapy.

(A) The schematic of samples collection and analyses performed for each patient. Top

boxes represent therapeutic phases, blue for chemotherapy, yellow for

immunotherapy, and purple for operation. TCR sequencing is indicated as circle.

Square and triangle represents ctDNA and RNA sequencing, respectively. Solid

shapes are defined as available data, while open shapes are defined as unavailable data. **(B)** Comparison of top 20 TCR clones at different therapeutic phases. **(C)** Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 × IQR], and the lower whisker is the max[min(x), Q1 - 1.5 × IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. **(D)** Comparison of large TCR clones at different therapeutic phases. **(E)** Comparison of large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon's Signed-Rank test was used for comparison in B-E (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, **** $p < 0.0001$). **(F)** Changes in diversity (Shannon index) of TCR clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, interquartile range.

Fig.4 Characterization of ctDNA and the alteration of tumor burden during treatment.

(A) Genomic landscape of mutations detected in plasma via ctDNA sequencing. Frequency of mutated genes were shown on the bar of middle and the proportion was shown in numerical form. Counts of mutations for each sample were displayed on top bar. Frequency for each of the six substitutions of the bases spectrum was shown on right. The scale lines below show the proportion of various mutation substitutions. **(B)** Changes in maxVAF across the entire course of therapy. Wilcoxon's Signed-Rank test was used for comparison. (*$p < 0.05$). ctDNA, circulating tumor DNA; maxVAF, maximal somatic variant allelic frequency.

Supplementary materials

Fig. S1 Dynamic change of top 20 TCR clones in the distinct phases.

(A) Changes of top 20 TCR clones of P1, P2, P3, P10, P11, and P12 in T0 to T1 (PH 1). **(B)** Changes of top 20 TCR clones of P1, P2, P5, P10, P11, and P12 in T1 to T2

(PH 2). **(C)** Changes of top 20 TCR clones of P2, P4, P10, P11, and P12 in T2 to T3

(PH 3). For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3),

and the black horizontal line represents the median; the upper whisker is the

min[max(x), Q3 + 1.5 × IQR], and the lower whisker is the max[min(x), Q1 - 1.5 ×

IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile,

and IQR = Q3 - Q1. Wilcoxon's Signed-Rank test was used for comparison (*$p <$*

0.05, **$p < 0.01$, ***$p < 0.001$, **** $p < 0.0001$). TCR, T-cell receptor; IQR,

interquartile range.

Fig. S2 Characterization of temporal dynamics of the T cell repertoire in the

longitudinal blood.

(A) Changes of the D50 index among patients. **(B)** Changes of Pielou index (evenness)

among patients. **(C)** Changes of clonality index among patients.

Fig. S3 Infiltration of CD4+ and CD8+ T lymphocytes after modified

neoadjuvant therapy.

(A) Relative proportion of lymphocytes was assessed by ImmunCellAI. **(B)** Relative

proportion of lymphocytes was assessed by xCell. For boxplots, each box indicates

the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents

the median; the upper whisker is the min[max(x), Q3 + 1.5 × IQR], and the lower

whisker is the max[min(x), Q1 - 1.5 × IQR], where x represents the data, Q3 is the

75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon's

Signed-Rank test was used for comparison. Tcm, central memory T cells; Tem,

Effector memory T cells; IQR, interquartile range.

Fig. S4 Change in maxVAF across different phases. For boxplots, each box

indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line

represents the median; the upper whisker is the min[max(x), Q3 + 1.5 × IQR], and the

lower whisker is the max[min(x), Q1 - 1.5 × IQR], where x represents the data, Q3 is

the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon's

Signed-Rank test was used for comparison. IQR, interquartile range.

Table S1. Clinical characteristics of patients

Table S2. List of treatment regimens

Table S3. List of top 20 TCR clones frequency across the whole modified therapy

Table S4. TCR characteristics across the whole modified therapy

Table S5. T cells abundance estimated by xCell

Table S6. T cells abundance estimated by ImmunCellAI

Table S7. Annotation of ctDNA somatic mutations